A study to find out whether symptoms of celiac disease that persist despite a gluten-free diet can be improved with the study drug ZED1227
Résumé de l'étude
In the study, participants are randomly assigned (like flipping a coin) to treatment with ZED1227 or placebo. The placebo looks like ZED1227 but contains no active ingredient. While participants take ZED1227 or placebo, they consume a snack bar containing a small amount of gluten three times a week (much less than is found in a slice of bread). The researchers want to investigate whether the drug helps even when patients inadvertently consume gluten through their normal diet. The consumption of these snack bars is referred to as simulated inadvertent gluten exposure (SIGE). The comparison between the patient group treated with ZED1227 and the placebo group will help researchers determine whether ZED1227 can alleviate the symptoms of celiac disease.
(BASEC)
Intervention étudiée
Efficacy of ZED1227 capsules for the treatment of celiac disease Endoscopy During this endoscopy, a biopsy is also performed, during which a small tissue sample is taken.
(BASEC)
Maladie en cours d'investigation
Celiac disease
(BASEC)
This study includes adult patients with celiac disease aged 18 to 80 years who meet the following main criteria for participation: - Participants have been diagnosed with celiac disease in the past, confirmed by biopsy or blood test. - They have attempted to maintain a gluten-free diet for at least one year prior to the study. - They continue to experience symptoms and intestinal damage despite the gluten-free diet. (BASEC)
Critères d'exclusion
Study participants cannot participate if they have other gastrointestinal diseases, severe food allergies, or signs of severe liver or kidney disease. (BASEC)
Lieu de l’étude
Berne, Zurich
(BASEC)
Sponsor
Dr. Falk Pharma GmbH, Freiburg im Breisgau / Deutschland
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
PD Dr. med. Jonas Zeitz
+44 3872 3955
Jonas.Zeitz@cluttergastrozentrum.chGastroZentrum Hirslanden, Witellikerstrasse 40, CH-8008 Zürich
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
09.08.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible